Aberrant and constitutive activation of signal transduction molecules are found in about 50% of primary AML bone marrow samples, enhancing the survival and proliferation of hematopoietic progenitor cells via the RAF/MEK/ERK cascade and the PI3K/AKT pathways that are dysregulated by mutations in receptor tyrosine kinases (RTK), Fms related receptor tyrosine kinase 3 (FLT3), N-Ras and K-Ras, and Kit [1,4]. This evidence concerns the gene AKT1 and acute myeloid leukemia.